WEBHELP
20.12.2022 15:02:09 CET | Business Wire | Press release
Webhelp, a leading global customer experience BPO player, has announced that this year it has achieved its highest global growth since inception, with operations now spanning more than 60 countries and with close to 125,000 people employed globally. Webhelp also won more than 50 industry awards this year, was recognized as a leader in the Gartner Magic Quadrant for Customer Service BPO, and earned top ratings in Customer Experience globally by Analyst Everest Group.
Across the year, Webhelp expanded in 24 new locations and six new countries – Thailand, Bosnia Herzegovina, Ghana, Israel, North Macedonia, and China – with a further 18 new site openings in existing locations across the United States, Latin America, Asia Pacific, and Europe, Middle East and Africa. Webhelp also experienced very strong client growth in 2022, onboarding over 240 new logo clients across the world, and welcoming more than 25,000 game-changers to the company. In line with increased demand, Webhelp continued to bolster hybrid and remote working through its Webhelp Anywhere proposition to deliver ultimate flexibility and scalability to clients and meet evolving employee work preferences.
“Growth is a team sport, and every single one of our people has had a part to play in this extraordinary year for Webhelp. We pride ourselves on the stellar work our game-changers deliver on behalf of our clients and look forward to continuing this trend in 2023, investing further in tech and people, to continue to provide the best possible solutions to our clients and their customers,” said Olivier Duha, CEO and Co-Founder of Webhelp.
Webhelp successfully completed a number of notable acquisitions and strategic investments, including the acquisition of Grupo Services in LATAM, the leading Brazilian providers of digitally enabled Customer Experience. In EMEA, Webhelp also joined forces with Uitblinqers to strengthen its position in the Dutch market and made additional investments with Gobeyond Partners, with the creation of a Nudge practice – a strategic unit that leverages behavioral economics to help organizations drive the best possible outcomes, through influencing customer behaviors.
“The past few years have taught us that connection and humanity are more important than ever. I’m incredibly proud to be at the helm of a fast-growing company that is leading the way in tech-enabled, human-centric Customer Experience,” continues Olivier Duha.
Webhelp has also been focusing on strengthening its sustainability and environmental social governance (ESG) practices. 12% of its workforce have been hired via an award-winning impact sourcing program, which includes hiring disadvantaged youth, reintegration initiatives to help female prisoners get into work, and an ecosystem that supports migrant and refugee employability. This year, Webhelp also partnered with SGS, the leading certification company, on a long-term initiative to safeguard frontline health and well-being.
Webhelp’s growth strategy underpins its desire to serve as a strategic blue ocean partner, leveraging a combination of global reach and hyper local expertise to unlock new value for its clients. Webhelp’s solutions and services are designed to be relevant and valuable for both digital native clients and businesses seeking to transform CX and drive strategic value and differentiation from it.
In 2023, Webhelp will continue its strategic growth, expanding further in new and current key locations across the world, including APAC, EMEA, and the Americas, as well as investments in people, technology, and innovation.
###
About Webhelp
Webhelp designs, delivers, and optimizes unforgettable human experiences for today’s digital world – creating game-changing customer journeys. From sales to service, content moderation to credit management, Webhelp is an end-to-end partner across all B2C and B2B customer journeys. Its over 110,000 passionate employees across more than 60 countries thrive on making a difference for the world’s most exciting brands. Webhelp is currently owned by its management and Groupe Bruxelles Lambert (Euronext: GBLB), a leading global investment holding, as of November 2019. For more information on Webhelp, visit Webhelp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005345/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
